168. エーラス・ダンロス症候群 [臨床試験数:7,薬物数:14(DrugBank:10),標的遺伝子数:17,標的パスウェイ数:53]
Searched query = "Ehlers Danlos syndrome"
The queries were searched in Public_title, Scientific_title, and Condition of the data. Export date: 11/21/2019, 11/20/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT04036305 | July 26, 2019 | 2 September 2019 | Local Anesthetic Response in Ehlers-Danlos Syndrome (EDS) and Healthy Volunteers | Local Anesthetic Response in Ehlers-Danlos Syndrome (EDS) and Healthy Volunteers | Ehlers-Danlos Syndrome;Anesthesia, Local | Drug: 0.9% Sodium Chloride Injection;Drug: Lidocaine Injection 2%;Drug: Bupivacaine Injection 0.5% | Vanderbilt University Medical Center | University of Calgary | Recruiting | 18 Years | N/A | All | 230 | Phase 3 | United States |
2 | NCT02597361 | January 2016 | 23 July 2018 | Angiotensin II Receptor Blockade in Vascular Ehlers Danlos Syndrome (ARCADE) | Angiotensin II Receptor Blockade in Vascular Ehlers Danlos Syndrome: a Double Blind, Randomized, Placebo Controlled, Multicenter Trial. | Ehlers-Danlos Syndrome, Vascular Type | Drug: Irbesartan;Drug: Placebo | Assistance Publique - Hôpitaux de Paris | Ministry of Health, France | Recruiting | 18 Years | 70 Years | All | 108 | Phase 3 | France |
3 | EUCTR2015-001065-76-FR | 28/09/2015 | 18 January 2016 | N/A | N/A - ARCADE | MedDRA version: 18.0 Level: PT Classification code 10014316 Term: Ehlers-Danlos syndrome System Organ Class: 10010331 - Congenital, familial and genetic disorders | Trade Name: IRBESARTAN Product Name: IRBESARTAN Pharmaceutical Form: Coated tablet INN or Proposed INN: irbesartan Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150- Pharmaceutical form of the placebo: Coated tablet Route of administration of the placebo: Oral use | ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | Authorised | Female: yes Male: yes | France | |||||
4 | NCT01446783 | September 2011 | 19 February 2015 | IGF-I Stimulation of Collagen Synthesis in Ehlers-Danlos Patients | IGF-I Stimulation of Collagen Synthesis in Ehlers-Danlos Patients | Ehlers-Danlos Syndrome, Classic | Drug: mecasermin;Drug: Saline | Bispebjerg Hospital | Not recruiting | 18 Years | N/A | Both | 15 | N/A | Denmark | |
5 | NCT01307527 | November 2008 | 19 February 2015 | Riboflavin Corneal Crosslinking for Brittle Cornea Syndrome and Ehlers-Danlos Syndrome Type VI | Brittle Cornea Syndrome;Ehlers-Danlos Syndrome Type 6 | Drug: Riboflavin;Device: Kera-X | Hadassah Medical Organization | Recruiting | 18 Years | N/A | Both | 1 | N/A | Israel | ||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
6 | NCT00190411 | October 2003 | 19 February 2015 | Celiprolol in Patients With Ehlers-Danlos Syndrome, Vascular Type | Prevention of Vascular Complications by BetaBlocker Treatment in Vascular Ehlers-Danlos Syndrome | EHLERS-DANLOS SYNDROME, TYPE IV, AUTOSOMAL DOMINANT;CHROMOSOME 2q31.2 DELETION SYNDROME | Drug: celiprolol;Drug: Control | Assistance Publique - Hôpitaux de Paris | Aventis Pharmaceuticals | Not recruiting | 15 Years | 65 Years | Both | 54 | Phase 4 | France |
7 | NCT00001966 | January 2000 | 19 February 2015 | Mind-Body Therapy for Pain in Ehlers-Danlos Syndrome | A Pilot Study of Mind-Body Therapy for Chronic Pain in Ehlers-Danlos Syndrome | Ehlers-Danlos Syndrome;Pain | Drug: Mind-body therapy | National Human Genome Research Institute (NHGRI) | Not recruiting | N/A | N/A | Both | 40 | Phase 2 | United States |